Hims & Hers HealthHIMS -3.02%83 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates HIMS with a GF Score™ of 83/100 and a GF Value™ of $39.38 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Hims & Hers Health ranks worse than 193798.26% on this metric.
Hims & Hers Health's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Hims & Hers Health's 5-Year Yield-on-Cost % or its related term are showing as below:
HIMS's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Hims & Hers Health (NYSE:HIMS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Hims & Hers Health 5-Year Yield-on-Cost % Related Terms
HIMS vs LNTH, LQDA, ALKS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's 5-Year Yield-on-Cost % falls into.
Hims & Hers Health 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Hims & Hers Health (HIMS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hims & Hers Health and its competitors. According to the industry distribution chart, Hims & Hers Health ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is Hims & Hers Health's 5-Year Yield-on-Cost % too high?
Hims & Hers Health's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Hims & Hers Health ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's 5-Year Yield-on-Cost % compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #999999 out of 516 companies for 5-Year Yield-on-Cost %. This places Hims & Hers Health in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.38, compared to a current price of $34.38 — trading 12.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Hims & Hers Health's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of $34.38 is trading 12.7% below its estimated GF Value™ of $39.38.
GuruFocus considers Hims & Hers Health to be Modestly Undervalued.
Key valuation signals for HIMS:
5-Year Yield-on-Cost %: 0.00
GF Value™: $39.38 vs. price of $34.38 (12.7% below fair value)
No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
83GF Score
Get the complete analysis for HIMS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIMS has been successfully added to your 